{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:08:12Z","timestamp":1789013292079,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yebeh.2026.111229","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T05:54:59Z","timestamp":1786254899000},"page":"111229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring the impact of controlled substance restrictions on epilepsy care in the United States: A neurologist survey"],"prefix":"10.1016","volume":"184","author":[{"given":"Lia","family":"de Leon Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-4413","authenticated-orcid":false,"given":"Amanda","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1772-8845","authenticated-orcid":false,"given":"Proleta","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9751-235X","authenticated-orcid":false,"given":"David C.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yebeh.2026.111229_b0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.0b013e318204a36a","article-title":"Estimating risk for developing epilepsy: a population-based study in Rochester","volume":"76","author":"Hesdorffer","year":"2011","journal-title":"Minnesota Neurology"},{"issue":"20","key":"10.1016\/j.yebeh.2026.111229_b0010","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","article-title":"Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study","volume":"71","author":"Faught","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yebeh.2026.111229_b0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.yebeh.2008.10.021","article-title":"Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy","volume":"14","author":"Ettinger","year":"2009","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111229_b0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1528-1167.2007.01414.x","article-title":"Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population","volume":"49","author":"Davis","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.111229_b0025","article-title":"On Time Saves lives: Survey Insights and Position Statement from the American Epilepsy Society on Barriers to Antiseizure Medication Access","volume":"25","author":"Bunch","year":"2026","journal-title":"Epilepsy Currents"},{"key":"10.1016\/j.yebeh.2026.111229_b0030","unstructured":"United States Drug Enforcement Administration. Drug scheduling. [Reviewed 2026 March 14]. Available from: https:\/\/www.dea.gov\/drug-information\/drug-scheduling."},{"key":"10.1016\/j.yebeh.2026.111229_b0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/epi4.12268","article-title":"Brief history of anti-seizure drug development","volume":"3","author":"Rho","year":"2018","journal-title":"Epilepsia Open"},{"issue":"77","key":"10.1016\/j.yebeh.2026.111229_b0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.yebeh.2017.10.007","article-title":"When adverse effects are seen as desirable: abuse potential of the newer generation antiepileptic drugs","volume":"1","author":"Hawkins","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111229_b0045","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/epi.17564","article-title":"Failure to use new breakthrough treatments for epilepsy","volume":"64","author":"Klein","year":"2023","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.yebeh.2026.111229_b0050","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1111\/epi.18546","article-title":"Drug Enforcement Administration scheduling negatively impacts patients with epilepsy: a call to action","volume":"66","author":"Ernst","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.111229_b0055","unstructured":"Controlled drugs and substances act (S.C. 1996, c. 19). [Reviewed 2026 March 14]. Available from: https:\/\/laws-lois.justice.gc.ca\/eng\/acts\/c-38.8\/FullText.html."},{"key":"10.1016\/j.yebeh.2026.111229_b0060","unstructured":"Diagnosis Code Requirement on Certain Pharmacy Claims. Missouri Department of Social Services. [Reviewed 2026 January 6]. Available from: https:\/\/mydss.mo.gov\/mhd\/hot-tips\/diagnosis-code-requirement-certain-pharmacy-claims."},{"key":"10.1016\/j.yebeh.2026.111229_b0065","unstructured":"Controlled Substance Prescribing Data by Condition. State Medical Board of Ohio. [Reviewed 2026 May 6]. Available from: https:\/\/med.ohio.gov\/for-licensees\/prescriber-resources\/icd-10-prescribing-tool."},{"issue":"1","key":"10.1016\/j.yebeh.2026.111229_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drugalcdep.2004.04.011","article-title":"Debating the controlled substances act","volume":"76","author":"Spillane","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.yebeh.2026.111229_b0075","first-page":"10","article-title":"The evolution of the overdose epidemic and CDC\u2019s research response: a commentary","volume":"15","author":"Holland","year":"2021","journal-title":"Drugs in Context"},{"key":"10.1016\/j.yebeh.2026.111229_b0080","unstructured":"Understanding the Opioid Overdose Epidemic. Centers for Disease Control and Prevention.2025 June 9. [Reviewed 2026 April 17]. Available from: https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html."},{"issue":"6","key":"10.1016\/j.yebeh.2026.111229_b0085","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0000000000000780","article-title":"Randomized, double-blind, placebo-and active comparator\u2013controlled crossover study evaluating the abuse potential of the antiepileptic drug lacosamide in healthy recreational drug users","volume":"37","author":"Schoedel","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2026.111229_b0090","unstructured":"Federal Register \u2013 The Daily Journal of the United States Government. Schedules of controlled substances: removal of fenfluramine from control. 23 December 2022. [Reviewed 2026 March 14]. Available from: https:\/\/www.federalregister.gov\/documents\/2022\/12\/23\/2022-27400\/schedules-of-controlled-substances-removal-of-fenfluramine-from-control."},{"key":"10.1016\/j.yebeh.2026.111229_b0095","unstructured":"Practical Neurology. Prescription pharmaceutical cannabidiol (Epidiolex) no longer a controlled substance. 6 April 2020. [Reviewed 2026 January 6]. Available from: https:\/\/practicalneurology.com\/news\/prescription-pharmaceutical-cannibidiol-epidiolex-no-longer-a-controlled-substance\/2469218\/."},{"issue":"4","key":"10.1016\/j.yebeh.2026.111229_b0100","first-page":"444","article-title":"What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse\/addiction and\/or aberrant drug-related behaviors?","volume":"9","author":"Fishbain","year":"2008","journal-title":"A structured evidence-based review Pain medicine"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111229_b0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1755-5949.2008.00073.x","article-title":"Low risk of development of substance dependence for barbiturates and clobazam prescribed as antiepileptic drugs: results from a questionnaire study","volume":"15","author":"Uhlmann","year":"2009","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"10.1016\/j.yebeh.2026.111229_b0110","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/cns.12399","article-title":"Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy","volume":"21","author":"Gauthier","year":"2015","journal-title":"CNS Neurosci Ther"},{"issue":"147","key":"10.1016\/j.yebeh.2026.111229_b0115","article-title":"A comprehensive analysis of jurisdiction-specific laws related to scheduling or required prescription drug monitoring of gabapentin in the United States, 2016\u20132024","volume":"1","author":"Combs","year":"2026","journal-title":"Int J Drug Policy"},{"issue":"9","key":"10.1016\/j.yebeh.2026.111229_b0120","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1093\/ajhp\/zxab486","article-title":"State-level response to gabapentin misuse in the United States: implications and future direction","volume":"79","author":"Karavolis","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111229_b0125","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/j.japh.2021.01.025","article-title":"Gabapentin controlled substance status","volume":"61","author":"Campbell","year":"2021","journal-title":"J Am Pharm Assoc"},{"issue":"2","key":"10.1016\/j.yebeh.2026.111229_b0130","first-page":"222","article-title":"Online availability of gabapentin and pregabalin and the impact of legal reclassification in the United Kingdom","volume":"30","author":"Hockenhull","year":"2023","journal-title":"Drugs: Education, Prevention and Policy"},{"key":"10.1016\/j.yebeh.2026.111229_b0135","first-page":"27","article-title":"Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study","volume":"1","author":"Ashworth","year":"2023","journal-title":"The Lancet Regional Health-Europe"},{"key":"10.1016\/j.yebeh.2026.111229_b0140","unstructured":"International Narcotics Control Board, 2020. List of psychotropic substances under international control: Green list. [Reviewed 2026 May 6]."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026003501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026003501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:28:52Z","timestamp":1789010932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505026003501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"alternative-id":["S1525505026003501"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111229","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the impact of controlled substance restrictions on epilepsy care in the United States: A neurologist survey","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111229"}}